
PRCT Stock Forecast & Price Target
PRCT Analyst Ratings
Bulls say
PROCEPT BioRobotics has demonstrated strong financial performance, reporting Q3’25 sales of $83.3 million, reflecting a significant year-over-year growth of 43%, which exceeded both internal targets and consensus estimates. The company is anticipating an acceleration in procedure volumes by more than 50% year-over-year during the second half of 2026, driven by effective commercial initiatives and a robust product pipeline. Additionally, the strong placement of 58 new capital systems in the quarter, surpassing previous guidance, signals increasing utilization in the urology sector, supporting sustainable double-digit growth in the company's revenue.
Bears say
PROCEPT BioRobotics Corp's forecasted financial performance has been negatively impacted by a fourth-quarter revenue that fell 19% below consensus expectations, forcing the company to meaningfully adjust its FY26 guidance downwards. The company’s anticipated sales for FY26 are projected at $390-410 million, which is 5% beneath consensus estimates, indicating challenges in both U.S. and international markets, particularly with US sales falling short by 7%. Furthermore, the reduction in handpiece sales, attributed to the cessation of bulk purchase discounts and inventory de-stocking, exacerbates the disappointing financial outlook and contributes to the significant volatility in the company's stock performance.
This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.
PRCT Analyst Forecast & Price Prediction
Start investing in PRCT
Order type
Buy in
Order amount
Est. shares
0 shares